Refine by
Vaccine And Drug Delivery Articles & Analysis
24 news found
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. With the rise of antibiotic-resistant bacteria posing a significant threat to global public health, Ace Therapeutics announces its new vaccine development services to ...
Boston: Microneedle technology, driven by high demand in dermatologic procedures and its versatile applications in drug delivery, vaccine administration, and disease diagnostics, faces challenges in its complex manufacturing process. ...
This comprehensive range, featuring tailored bio-inks for specific applications, paves the way for revolutionary advancements in regenerative medicine, drug discovery, and beyond. Bio-ink is a material used in the 3D bioprinting industry to create structures that can imitate natural tissues and organs. ...
ByMatexcel
In the face of global health crises such as the COVID-19 pandemic, the development and production of vaccines have become paramount to safeguarding public health and restoring normalcy. Among the various vaccine technologies, mRNA vaccines have emerged as a groundbreaking solution, offering promising results in the fight against infectious diseases. Alfa Chemistry, a renowned scientific research ...
Alfa Chemistry, known as a chemical supplier for various high-quality chemicals and materials for both academia and the industry, has recently extended its offering scope to vaccine related products, including but not limited to: vaccine excipients, nucleic acid delivery excipients, cell culture media and pharmaceutical packaging. “Always bearing in mind that what customers truly need is the top ...
Biolingus IP II GmbH and the CHA Vaccine Institute Co., Ltd., with support from the Korean biotech company PanGen Biotech Inc., will collaborate to develop a sublingual vaccine for COVID. The project has received research funding from The Research Investment for Global Health Technology Fund (The RIGHT Fund). The RIGHT Fund is a Public-Private Partnership (PPP) funding agency between the ...
Ocean Biomedical’s initial core portfolios in oncology, fibrosis, and infectious diseases – all based on new target discoveries enabling first-in-class drug and vaccine candidates – have been developed through grants totaling $123.9 million. ...
Dr. Mark Prausnitz, co-founder and Chief Scientific Advisor of Micron Biomedical (“Micron”), today presented Micron’s technology for the simple administration of vaccines and therapeutics at a White House panel discussion titled Innovation in Vaccine Delivery chaired by Dr. Francis Collins. This summit outlined a path toward innovative, next-generation COVID-19 vaccines and ...
Australian biotechnology company, Vaxxas Pty Ltd (Vaxxas), in collaboration with the University of Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, has completed a study assessing the usability and acceptability of its novel High-Density Microarray Patch (HD-MAP) to administer vaccines. The HD-MAP is Vaxxas’ proprietary vaccine patch technology, representing a ...
Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy Pfizer gains option to license Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development Pfizer Inc. (NYSE: PFE) and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems ...
Things that are freeze-dried: Astronaut food. Emergency rations. And, just maybe, some future COVID-19 vaccines. Freeze-drying is a method for removing water from a product. First, you freeze the item you’re trying to dehydrate, causing any water in it to become ice. Then, you remove the ice through a process called sublimation, in which ice turns directly into vapor under low pressure. In ...
Following months of collaborative development work, Aerogen® (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) have announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine Convidecia™ utilizing Aerogen’s proprietary vibrating mesh ...
ByAerogen
BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $599,981, two-year Phase I Small Business Innovation Research (SBIR) under Award No. 1R43AI165089-01, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to pursue development of a potentially life-saving vaccine technology to address the ongoing ...
Abera Bioscience AB (“Abera” or “the Company”) continues to improve its vaccine platform in collaboration with researchers at Vrije Universiteit Amsterdam. An article was recently published in the peer-reviewed journal Microbial Cell Factories by researchers Trang H. Phan, Coen Kuijl and Peter van Ulsen of Vrije Universiteit Amsterdam in collaboration with Abera’s ...
Enesi Pharma Ltd (“Enesi”), an innovative biotechnology company developing next-generation vaccination products, targeting infectious diseases and emergent threat pathogens, enabled by its world leading ImplaVax® technologies, is delighted to announce the appointment of Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations. ...
Recently, several studies have shown that exosomes express some lipids and cell adhesion molecules and ligands naturally targeting certain types of recipient cells, which suggests that exosomes have natural targeting ability based on donor cells and can act as an efficient tool for targeting delivery. With years of experiences in exosome technology, Creative Biolabs has combined ...
Company’s aerosol drug delivery technology used in Phase 1 clinical trial to deliver inhaled type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults without COVID-19 from China The Aerogen Solo is a closed-system, single-patient-use aerosol drug delivery technology1 that mitigates the transmission of ...
ByAerogen
(“Micron” or the “Company”), a leader in dissolving, microneedle-based vaccine and drug delivery, today announced that it has initiated a Phase 1/2 clinical trial of its microneedle-based measles-rubella (“MR”) vaccine. The trial will assess the safety, tolerability and immunogenicity of an MR ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella. ...
EuCorVac-19 is a liquid injection that can be stored and distributed at refrigerated temperatures, unlike the ultra-cold storage the PfizerBioNTech vaccine requires. The candidate generated strong immune responses in animal models and was approved for combined phase 1 and 2 clinical trials by the South Korean Ministry of Food and Drug Safety in January. ...